Designing oncology clinical trials has become increasingly complex as scientific innovation accelerates and treatment paradigms evolve. Modern oncology trial design must accommodate heterogeneous tumor biology, biomarker-defined subpopulations and continuously shifting standards of care. What was once a relatively standardized approach to protocol development has evolved into a highly nuanced process requiring scientific precision, operational feasibility and real-world relevance.
At the same time, sponsors must navigate fragmented patient populations, geographic variation in clinical practice and rising expectations from regulators around diversity, patient-centricity and real-world applicability. Studies are no longer evaluated solely on scientific rigor — they must also demonstrate that findings are generalizable across patient populations and aligned with real-world care delivery.
These dynamics often result in overly complex protocols — driven by restrictive eligibility criteria, intensive procedures and misalignment with real-world practice. This results in a smaller addressable patient population, higher patient and site burden and a greater likelihood that trial efficacy does not translate into real-world effectiveness. Meanwhile, although oncology patients may be willing to undergo extensive procedures in hopes of effectively treating their cancer, given the significant disease burden inherent with oncology, sponsors would do well to address any incremental inefficiencies in their trial design.
In parallel, relying solely on static treatment guidelines without considering real-world evidence, introduces additional risk. Clinical practice evolves rapidly and at an unpredictable pace, with guidelines often lagging emerging treatment patterns. As a result, comparator arms or biomarker strategies that appear appropriate in theory may not reflect how patients are actually treated in practice. This misalignment can lead to protocol amendments, enrollment delays and increased operational costs, once the study is underway.
A Data-Informed Protocol Assessment for Oncology (DIPA-O) is a structured, evidence-based approach that evaluates oncology trial design using real-world clinical data, competitive benchmarks and advanced analytics. Rather than relying on assumptions or fragmented datasets, DIPA-O enables sponsors to systematically test protocol decisions against the realities of clinical practice.
By assessing protocol assumptions early in the design process, this approach helps sponsors make more informed trade-offs between scientific rigor, feasibility and patient access. Importantly, it shifts protocol development from a reactive exercise, where issues are addressed after they emerge to a proactive strategy focused on anticipating and mitigating risk before execution begins.
This structured assessment also provides a consistent framework for evaluating design decisions across studies, enabling greater transparency and alignment across clinical, operational and strategic stakeholders.
Six key dimensions underpin effective oncology protocol optimization:
Together, these dimensions provide a comprehensive, multidimensional view of clinical trial feasibility. Rather than evaluating protocol components in isolation, sponsors can identify how different design elements interact to either support or hinder study success.
For example, tightening eligibility criteria may improve internal validity but significantly reduce patient availability. Similarly, adding study procedures may enhance data collection but increase patient and site burden. Understanding these interdependencies is critical to optimizing protocol design without compromising scientific intent.
While the core DIPA-O framework addresses foundational design elements, advanced oncology analytics introduce a deeper level of precision. These capabilities enable sponsors to move beyond generalized assumptions and incorporate targeted, context-specific insights that reflect the complexity of modern oncology care.
Key capabilities include:
These analytics are particularly valuable in global oncology studies, where variability in care delivery, treatment access and diagnostic infrastructure can significantly impact feasibility. By incorporating these insights early, sponsors can design protocols that are both globally consistent and locally executable.
The value of a data-informed approach becomes most apparent when examining how insights translate into concrete design improvements.
Optimizing eligibility criteria:
A sponsor designing an oncology study may initially restrict eligibility to patients with a specific biomarker and limited prior therapy exposure. Data-informed assessment may reveal that only a small proportion of patients meet these combined criteria in target geographies. By refining thresholds while maintaining scientific intent, the sponsor can expand the addressable population and improve enrollment feasibility.
Reducing unnecessary procedures:
Protocols often include frequent imaging or invasive procedures based on conservative assumptions. Analysis of real-world clinical practice may show that these interventions occur less frequently without compromising patient management. Reducing non-essential procedures can decrease patient burden, improve retention and streamline site operations.
Improving comparator selection:
A comparator arm based on historical guidelines may not reflect current clinical practice. Real-world treatment pattern analysis can reveal shifts toward newer therapies or regional variability in standard of care. Incorporating these insights allows sponsors to design more relevant and feasible comparator strategies, improving both enrollment and regulatory positioning.
These examples illustrate how data-informed insights enable sponsors to refine protocol design in ways that are practical, impactful and aligned with real-world clinical realities.
Oncology protocol design is inherently a process of managing trade-offs. Decisions related to eligibility, procedures, comparator selection and biomarker inclusion must balance competing priorities, including:
These decisions are highly interconnected and can significantly influence trial outcomes. For example, expanding eligibility criteria may increase enrollment potential but introduce variability in patient populations. Conversely, narrowing criteria may improve study precision but reduce feasibility.
IQVIA combines proprietary real-world evidence, advanced analytics and deep domain expertise to help sponsors evaluate these trade-offs holistically. Rather than assessing individual design elements in isolation, this integrated approach enables a comprehensive understanding of how each decision impacts recruitment timelines, operational complexity, patient experience and overall trial success.
This perspective transforms protocol design into a strategic, data-informed exercise — enabling sponsors to make decisions with greater confidence and clarity.
Protocols that are aligned with real-world clinical practice and patient realities are more likely to succeed operationally. By identifying risks early and optimizing design decisions before execution, data-informed approaches can help reduce the need for costly amendments and mitigate delays.
Tailored eligibility criteria can improve patient access and recruitment rates. Streamlined procedures reduce burden on patients and sites. More representative comparator arms can enhance trial relevance and acceptance among investigators and regulators.
Collectively, these improvements contribute to more efficient study execution, stronger data generation and improved likelihood of trial success.
In an environment where oncology trials are becoming increasingly complex and resource-intensive, data-informed protocol optimization is no longer optional — it is essential to achieving both scientific and operational objectives.
Explore how IQVIA’s Data-Informed Protocol Assessment can optimize oncology trial design, improve feasibility and reduce execution risk. By leveraging advanced analytics and real-world evidence, sponsors can transform protocol design into a strategic advantage — enabling more efficient trials, stronger outcomes and greater confidence in execution.
Key factors include eligibility criteria, patient burden, study procedures, treatment patterns, geographic variability and access to diagnostics such as biomarker testing.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.
.svg){kind=icon}
